Breaking News, Collaborations & Alliances

PolyActiva, RareSight Partner to Develop Therapies for Rare Pediatric Retinal Diseases

The research collaboration agreement will offer new chemical entity (NCE)-eligible pro-drug candidates to people affected by blinding eye conditions.

Author Image

By: Charlie Sternberg

Associate Editor

PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight Inc., an ophthalmology-focused life sciences company committed to advancing therapies for inherited retinal diseases (IRDs), have joined forces to develop first-in-class therapies for rare pediatric retinal diseases that currently have no approved drug treatments. The research collaboration agreement, leveraging PolyActiva’s ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters